Pharmacopedia - Recent changes [en]

Methylphenidate

MDElliottMD — Tue, 16 Jun 2026 06:46:26 GMT

B3 edit-4: Molina 2009 ref for MTA long-term claim (PMID 19318991); en-dash re-anchor; home-claude, mark-greenlit

← Older revision		Revision as of 06:46, 16 June 2026
Line 22:		Line 22:
	Methylphenidate was placed on Schedule II of the U.S. Controlled Substances Act in 1971, alongside amphetamine and cocaine, where it has remained.<ref name="csa-1971">U.S. Drug Enforcement Administration. Controlled Substances Act (21 U.S.C. §§ 801–971), Schedule II. 21 CFR 1308.12.</ref> The 1990s and 2000s saw a marked expansion of ADHD diagnosis and methylphenidate prescribing in the United States, accompanied by the development of extended-release formulations (Concerta osmotic-pump tablets approved 2000; Ritalin LA 2002; Metadate CD 2001; Daytrana transdermal patch 2006) that reduced the practical burden of multiple-times-daily dosing and supported broader adult use.		Methylphenidate was placed on Schedule II of the U.S. Controlled Substances Act in 1971, alongside amphetamine and cocaine, where it has remained.<ref name="csa-1971">U.S. Drug Enforcement Administration. Controlled Substances Act (21 U.S.C. §§ 801–971), Schedule II. 21 CFR 1308.12.</ref> The 1990s and 2000s saw a marked expansion of ADHD diagnosis and methylphenidate prescribing in the United States, accompanied by the development of extended-release formulations (Concerta osmotic-pump tablets approved 2000; Ritalin LA 2002; Metadate CD 2001; Daytrana transdermal patch 2006) that reduced the practical burden of multiple-times-daily dosing and supported broader adult use.

	The largest independent comparative-effectiveness data source on methylphenidate is the Multimodal Treatment of ADHD (MTA) study, a National Institute of Mental Health-funded randomized controlled trial published in 1999 that compared medication management (predominantly methylphenidate), behavioral therapy, the combination of both, and community standard care in 579 children aged 7–9 with ADHD. The medication and combined arms produced significantly greater improvement in ADHD symptoms than the behavioral or community arms at 14 months.<ref name="mta1999">MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Archives of General Psychiatry. 1999;56(12):1073–1086.</ref> Long-term follow-ups have moderated the short-term superiority finding, with diminishing between-group differences by 36 months and broadly comparable functional outcomes across arms by adulthood.~~{{citation needed}}~~<~~!-- Candidate:~~ Swanson JM et al on MTA ~~long~~-~~term follow~~-~~ups, multiple papers 2007–2019~~. ~~Verify exact~~ PMID ~~at publish~~. -->		The largest independent comparative-effectiveness data source on methylphenidate is the Multimodal Treatment of ADHD (MTA) study, a National Institute of Mental Health-funded randomized controlled trial published in 1999 that compared medication management (predominantly methylphenidate), behavioral therapy, the combination of both, and community standard care in 579 children aged 7–9 with ADHD. The medication and combined arms produced significantly greater improvement in ADHD symptoms than the behavioral or community arms at 14 months.<ref name="mta1999">MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Archives of General Psychiatry. 1999;56(12):1073–1086.</ref> Long-term follow-ups have moderated the short-term superiority finding, with diminishing between-group differences by 36 months and broadly comparable functional outcomes across arms by adulthood.<ref name="molina2009">Molina BSG, Hinshaw SP, Swanson JM, et al. The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry. 2009;48(5):484-500. PMID 19318991.</ref>

	Cardiovascular safety in long-term outpatient use was characterized by Cooper and colleagues in a large 2011 cohort study published in the New England Journal of Medicine: among 1,200,438 children and young adults receiving ADHD medications, no significant association with serious cardiovascular events was found compared with non-users, after adjustment for cardiovascular risk factors.<ref name="cooper2011">Cooper WO, Habel LA, Sox CM, et al. ADHD drugs and serious cardiovascular events in children and young adults. New England Journal of Medicine. 2011;365(20):1896–1904.</ref> A companion JAMA study by Habel and colleagues reached similar conclusions in adults.<ref name="habel2011">Habel LA, Cooper WO, Sox CM, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA. 2011;306(24):2673–2683.</ref> These analyses attenuated the post-2006 cardiac-safety concerns that had driven the peripheral vasculopathy and sudden-cardiac-death warnings, though the FDA warnings remain in place.		Cardiovascular safety in long-term outpatient use was characterized by Cooper and colleagues in a large 2011 cohort study published in the New England Journal of Medicine: among 1,200,438 children and young adults receiving ADHD medications, no significant association with serious cardiovascular events was found compared with non-users, after adjustment for cardiovascular risk factors.<ref name="cooper2011">Cooper WO, Habel LA, Sox CM, et al. ADHD drugs and serious cardiovascular events in children and young adults. New England Journal of Medicine. 2011;365(20):1896–1904.</ref> A companion JAMA study by Habel and colleagues reached similar conclusions in adults.<ref name="habel2011">Habel LA, Cooper WO, Sox CM, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA. 2011;306(24):2673–2683.</ref> These analyses attenuated the post-2006 cardiac-safety concerns that had driven the peripheral vasculopathy and sudden-cardiac-death warnings, though the FDA warnings remain in place.

Acetaminophen

MDElliottMD — Mon, 15 Jun 2026 07:34:06 GMT

Acetaminophen safety depth (launch gate): Overdose+toxicity (Rumack-Matthew nomogram, NAC regimens) + Combination products/325mg FDA cap sections; template byte-preserved; multi-review-passed + mark-greenlit

@@ Line 18: / Line 18: @@
 | mechanism         = <vote slug="apap-mech-claim">Acetaminophen's analgesic and antipyretic actions are incompletely characterized; central COX inhibition (particularly the COX-2 splice variant sometimes called COX-3, and inhibition of arachidonic acid pathways in CNS at low peroxide concentrations) is the leading hypothesis, with possible contribution from descending serotonergic pathways and TRPV1 modulation by the AM404 metabolite.</vote> The absence of meaningful peripheral cyclooxygenase inhibition explains the lack of antiplatelet and anti-inflammatory effect compared with NSAIDs, and the gastroprotective profile. '''Dose-dependent hepatotoxicity''' via the CYP2E1 metabolite N-acetyl-p-benzoquinone imine (NAPQI) once glutathione is depleted; N-acetylcysteine is the antidote and is most effective within 8-10 hours of overdose<ref name="tylenol-label" />.
 }}
 == References ==

Template:MedTemplate

MDElliottMD — Sun, 14 Jun 2026 21:33:10 GMT

Launch Gate 2: per-medicine disclaimer band (mark-approved)

← Older revision		Revision as of 21:33, 14 June 2026
Line 62:		Line 62:
	{{{references}}}}}</div><div class="med-rail"><div class="med-rail-inner"><div class="med-channel ch-pharmacy"><div class="ch-head"><span class="ch-mark"></span><span class="ch-name">Pharmacy</span></div>{{#if:{{{starting_dose\|}}}\|<div class="med-field"><div class="fl">Starting dose</div><div class="fv">{{{starting_dose}}}</div></div>}}{{#if:{{{preparations\|}}}\|<div class="med-field"><div class="fl">Preparations</div><div class="fv">{{{preparations}}}</div></div>}}{{#if:{{{fda_max\|}}}\|<div class="med-field"><div class="fl">US FDA Max</div><div class="fv">{{{fda_max}}}</div></div>}}{{#if:{{{pill_id\|}}}\|<div class="med-field"><div class="fl">Pill ID</div><div class="fv"><div class="pcp-pill-id"><div class="mw-collapsible mw-collapsed" data-expandtext="Show pill identifiers" data-collapsetext="Hide pill identifiers">		{{{references}}}}}</div><div class="med-rail"><div class="med-rail-inner"><div class="med-channel ch-pharmacy"><div class="ch-head"><span class="ch-mark"></span><span class="ch-name">Pharmacy</span></div>{{#if:{{{starting_dose\|}}}\|<div class="med-field"><div class="fl">Starting dose</div><div class="fv">{{{starting_dose}}}</div></div>}}{{#if:{{{preparations\|}}}\|<div class="med-field"><div class="fl">Preparations</div><div class="fv">{{{preparations}}}</div></div>}}{{#if:{{{fda_max\|}}}\|<div class="med-field"><div class="fl">US FDA Max</div><div class="fv">{{{fda_max}}}</div></div>}}{{#if:{{{pill_id\|}}}\|<div class="med-field"><div class="fl">Pill ID</div><div class="fv"><div class="pcp-pill-id"><div class="mw-collapsible mw-collapsed" data-expandtext="Show pill identifiers" data-collapsetext="Hide pill identifiers">
	{{{pill_id}}}		{{{pill_id}}}
	</div></div></div></div>}}</div><div class="med-channel ch-uses"><div class="ch-head"><span class="ch-mark"></span><span class="ch-name">Common uses</span></div><pharmaCommonUses>{{{uses\|}}}</pharmaCommonUses></div>{{#if:{{{structure\|}}}\|<div class="med-channel ch-structure"><div class="ch-head"><span class="ch-mark"></span><span class="ch-name">Structure</span></div><div class="med-structure">[[File:{{{structure}}}\|frameless\|{{{structuresize\|240px}}}\|alt=Structure of {{{generic\|{{PAGENAME}}}}}]]</div></div>}}<div class="med-channel ch-classes"><div class="ch-head"><span class="ch-mark"></span><span class="ch-name">Classification(s)</span></div>{{#if:{{{classes\|}}}\|<div class="med-field"><div class="fl">Classes</div><div class="fv">{{{classes}}}</div></div>}}</div><div class="med-channel ch-pharmacology"><div class="ch-head"><span class="ch-mark"></span><span class="ch-name">Pharmacology</span></div>{{#if:{{{routes\|}}}\|<div class="med-field"><div class="fl">Routes</div><div class="fv">{{{routes}}}</div></div>}}{{#if:{{{onset\|}}}\|<div class="med-field"><div class="fl">Onset</div><div class="fv">{{{onset}}}</div></div>}}{{#if:{{{duration\|}}}\|<div class="med-field"><div class="fl">Duration</div><div class="fv">{{{duration}}}</div></div>}}{{#if:{{{halflife\|}}}\|<div class="med-field"><div class="fl">Half-life</div><div class="fv">{{{halflife}}}</div></div>}}{{#if:{{{bioavailability\|}}}\|<div class="med-field"><div class="fl">Bioavailability</div><div class="fv">{{{bioavailability}}}</div></div>}}{{#if:{{{pregnancy\|}}}\|<div class="med-field"><div class="fl">Pregnancy</div><div class="fv">{{{pregnancy}}}</div></div>}}{{#if:{{{legal\|}}}\|<div class="med-field"><div class="fl">Legal status</div><div class="fv">{{{legal}}}</div></div>}}{{#if:{{{mechanism\|}}}\|<div class="med-field"><div class="fl">Purported mechanism</div><div class="fv">{{{mechanism}}}</div></div>}}</div></div></div></div>[[Category:Medicines]]</div></includeonly><noinclude>		</div></div></div></div>}}</div><div class="med-channel ch-uses"><div class="ch-head"><span class="ch-mark"></span><span class="ch-name">Common uses</span></div><pharmaCommonUses>{{{uses\|}}}</pharmaCommonUses></div>{{#if:{{{structure\|}}}\|<div class="med-channel ch-structure"><div class="ch-head"><span class="ch-mark"></span><span class="ch-name">Structure</span></div><div class="med-structure">[[File:{{{structure}}}\|frameless\|{{{structuresize\|240px}}}\|alt=Structure of {{{generic\|{{PAGENAME}}}}}]]</div></div>}}<div class="med-channel ch-classes"><div class="ch-head"><span class="ch-mark"></span><span class="ch-name">Classification(s)</span></div>{{#if:{{{classes\|}}}\|<div class="med-field"><div class="fl">Classes</div><div class="fv">{{{classes}}}</div></div>}}</div><div class="med-channel ch-pharmacology"><div class="ch-head"><span class="ch-mark"></span><span class="ch-name">Pharmacology</span></div>{{#if:{{{routes\|}}}\|<div class="med-field"><div class="fl">Routes</div><div class="fv">{{{routes}}}</div></div>}}{{#if:{{{onset\|}}}\|<div class="med-field"><div class="fl">Onset</div><div class="fv">{{{onset}}}</div></div>}}{{#if:{{{duration\|}}}\|<div class="med-field"><div class="fl">Duration</div><div class="fv">{{{duration}}}</div></div>}}{{#if:{{{halflife\|}}}\|<div class="med-field"><div class="fl">Half-life</div><div class="fv">{{{halflife}}}</div></div>}}{{#if:{{{bioavailability\|}}}\|<div class="med-field"><div class="fl">Bioavailability</div><div class="fv">{{{bioavailability}}}</div></div>}}{{#if:{{{pregnancy\|}}}\|<div class="med-field"><div class="fl">Pregnancy</div><div class="fv">{{{pregnancy}}}</div></div>}}{{#if:{{{legal\|}}}\|<div class="med-field"><div class="fl">Legal status</div><div class="fv">{{{legal}}}</div></div>}}{{#if:{{{mechanism\|}}}\|<div class="med-field"><div class="fl">Purported mechanism</div><div class="fv">{{{mechanism}}}</div></div>}}</div></div></div></div><div class="med-disclaimer">Pharmacopedia is intended for reference. Nothing here is advice. In an emergency call 911; US Poison Control 1-800-222-1222. See the [[Pharmacopedia:General disclaimer\|full disclaimer]].</div>[[Category:Medicines]]</div></includeonly><noinclude>
	{{#cargo_declare:_table=Medicines		{{#cargo_declare:_table=Medicines
	\| generic=String		\| generic=String

Pharmacopedia:General disclaimer

MDElliottMD — Sun, 14 Jun 2026 21:32:24 GMT

Launch Gate 2: medical disclaimer page (fixes footer 404; mark-approved)

New page

__NOTOC__
'''Pharmacopedia is intended for reference. Nothing here is advice.'''

If you're looking for advice, please speak to a clinician directly. Nothing here can replace a clinician's expertise. If you have a medical question or emergency, consult a licensed clinician or call emergency services. For overdose or poisoning in the United States, call Poison Control at 1-800-222-1222.

This disclaimer applies to every page on Pharmacopedia.

Warfarin

MDElliottMD — Sat, 13 Jun 2026 18:04:49 GMT

B3 citation patch (home-claude, PM-approved): clear [citation needed] with verified ref

← Older revision		Revision as of 18:04, 13 June 2026
Line 14:		Line 14:
	\| halflife = 36-42 hours (R/S enantiomers differ; S-warfarin is 2-5× more potent and cleared by CYP2C9)<ref name="coumadin-label">FDA Prescribing Information, Coumadin (warfarin sodium), Bristol-Myers Squibb, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/009218s108lbl.pdf</ref>		\| halflife = 36-42 hours (R/S enantiomers differ; S-warfarin is 2-5× more potent and cleared by CYP2C9)<ref name="coumadin-label">FDA Prescribing Information, Coumadin (warfarin sodium), Bristol-Myers Squibb, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/009218s108lbl.pdf</ref>
	\| bioavailability = ~100% (oral)<ref name="coumadin-label" />		\| bioavailability = ~100% (oral)<ref name="coumadin-label" />
	\| pregnancy = '''Contraindicated in pregnancy''' (warfarin embryopathy, fetal hemorrhage) except in mechanical mitral valves where the maternal mortality of alternative agents may exceed fetal risk.~~{{citation needed}}~~		\| pregnancy = '''Contraindicated in pregnancy''' (warfarin embryopathy, fetal hemorrhage) except in mechanical mitral valves where the maternal mortality of alternative agents may exceed fetal risk.<ref name="coumadin-label" />
	\| legal = [[USLegal:Prescription only\|Rx-only]] in US		\| legal = [[USLegal:Prescription only\|Rx-only]] in US
	\| mechanism = <vote slug="warfarin-mech-claim">Warfarin inhibits vitamin K epoxide reductase complex 1 (VKORC1), preventing regeneration of reduced vitamin K and γ-carboxylation of glutamate residues on factors II, VII, IX, X, and proteins C and S; the result is hypofunctional clotting factors, the most clinically important being factor II (prothrombin, half-life ~60 hours) whose depletion drives the steady-state anticoagulant effect.</vote> CYP2C9 (S-warfarin clearance) and VKORC1 (drug target) polymorphisms together explain 30-50% of inter-individual dosing variance and are the prototype pharmacogenomic target in clinical use<ref name="cpic-warfarin">CPIC Guideline for CYP2C9, VKORC1, CYP4F2, and Warfarin, 2017. https://cpicpgx.org/guidelines/guideline-for-warfarin-and-cyp2c9-and-vkorc1/</ref>. Reversal: vitamin K, 4F-PCC for life-threatening bleeding (FFP if PCC unavailable).		\| mechanism = <vote slug="warfarin-mech-claim">Warfarin inhibits vitamin K epoxide reductase complex 1 (VKORC1), preventing regeneration of reduced vitamin K and γ-carboxylation of glutamate residues on factors II, VII, IX, X, and proteins C and S; the result is hypofunctional clotting factors, the most clinically important being factor II (prothrombin, half-life ~60 hours) whose depletion drives the steady-state anticoagulant effect.</vote> CYP2C9 (S-warfarin clearance) and VKORC1 (drug target) polymorphisms together explain 30-50% of inter-individual dosing variance and are the prototype pharmacogenomic target in clinical use<ref name="cpic-warfarin">CPIC Guideline for CYP2C9, VKORC1, CYP4F2, and Warfarin, 2017. https://cpicpgx.org/guidelines/guideline-for-warfarin-and-cyp2c9-and-vkorc1/</ref>. Reversal: vitamin K, 4F-PCC for life-threatening bleeding (FFP if PCC unavailable).

Desiccated thyroid

MDElliottMD — Sat, 13 Jun 2026 18:04:47 GMT

B3 citation patch (home-claude, PM-approved): clear [citation needed] with verified ref

← Older revision		Revision as of 18:04, 13 June 2026
Line 16:		Line 16:
	\| halflife = T4 ~7 days; T3 ~1 day<ref name="armour-label" />		\| halflife = T4 ~7 days; T3 ~1 day<ref name="armour-label" />
	\| bioavailability = Variable; reduced by food, calcium, iron, PPIs<ref name="armour-label" />		\| bioavailability = Variable; reduced by food, calcium, iron, PPIs<ref name="armour-label" />
	\| pregnancy = Synthetic levothyroxine is the standard-of-care in pregnancy; desiccated thyroid use in pregnancy is not well studied~~{{citation needed}}~~		\| pregnancy = Synthetic levothyroxine is the standard-of-care in pregnancy; desiccated thyroid use in pregnancy is not well studied.<ref name="ata2017-preg">Alexander EK, Pearce EN, Brent GA, et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid. 2017;27(3):315-389. PMID 28056690.</ref>
	\| legal = [[USLegal:Prescription only\|Rx-only]] in US		\| legal = [[USLegal:Prescription only\|Rx-only]] in US
	\| mechanism = <vote slug="desiccated-thyroid-mech-claim">Desiccated thyroid supplies both T4 and T3 in a roughly 4:1 ratio; T4 is peripherally deiodinated to T3, but exogenous T3 supplementation produces faster onset and supraphysiologic post-dose peaks that synthetic T4 monotherapy avoids.</vote> Brand-to-brand and lot-to-lot variability in T3:T4 ratio is greater than with synthetic levothyroxine, which is why endocrine guidelines prefer the synthetic<ref name="armour-label" />.		\| mechanism = <vote slug="desiccated-thyroid-mech-claim">Desiccated thyroid supplies both T4 and T3 in a roughly 4:1 ratio; T4 is peripherally deiodinated to T3, but exogenous T3 supplementation produces faster onset and supraphysiologic post-dose peaks that synthetic T4 monotherapy avoids.</vote> Brand-to-brand and lot-to-lot variability in T3:T4 ratio is greater than with synthetic levothyroxine, which is why endocrine guidelines prefer the synthetic<ref name="armour-label" />.

Liothyronine

MDElliottMD — Sat, 13 Jun 2026 18:04:45 GMT

B3 citation patch (home-claude, PM-approved): clear [citation needed] with verified ref

← Older revision		Revision as of 18:04, 13 June 2026
Line 14:		Line 14:
	\| halflife = ~1 day (much shorter than T4's ~7 days)<ref name="cytomel-label">FDA Prescribing Information, Cytomel (liothyronine sodium), Pfizer/King, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/010379s055lbl.pdf</ref>		\| halflife = ~1 day (much shorter than T4's ~7 days)<ref name="cytomel-label">FDA Prescribing Information, Cytomel (liothyronine sodium), Pfizer/King, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/010379s055lbl.pdf</ref>
	\| bioavailability = ~95% (oral)<ref name="cytomel-label" />		\| bioavailability = ~95% (oral)<ref name="cytomel-label" />
	\| pregnancy = T4 (levothyroxine) is the first-line in pregnancy; T3 is rarely needed.~~{{citation needed}}~~		\| pregnancy = T4 (levothyroxine) is the first-line in pregnancy; T3 is rarely needed.<ref name="ata2017-preg">Alexander EK, Pearce EN, Brent GA, et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid. 2017;27(3):315-389. PMID 28056690.</ref>
	\| legal = [[USLegal:Prescription only\|Rx-only]] in US		\| legal = [[USLegal:Prescription only\|Rx-only]] in US
	\| mechanism = <vote slug="liothyronine-mech-claim">Liothyronine is bioidentical T3 (triiodothyronine), the active thyroid hormone that binds nuclear thyroid hormone receptors with ~10× the affinity of T4; T4 (levothyroxine) is essentially a prodrug peripherally deiodinated to T3.</vote> Direct T3 supplementation bypasses peripheral deiodination, useful in myxedema coma (rapid clinical effect needed) and in some refractory hypothyroidism (combination T4+T3, controversial). Short half-life produces fluctuating serum levels with intermittent supraphysiologic peaks — one reason T4 monotherapy remains the practical standard<ref name="cytomel-label" />.		\| mechanism = <vote slug="liothyronine-mech-claim">Liothyronine is bioidentical T3 (triiodothyronine), the active thyroid hormone that binds nuclear thyroid hormone receptors with ~10× the affinity of T4; T4 (levothyroxine) is essentially a prodrug peripherally deiodinated to T3.</vote> Direct T3 supplementation bypasses peripheral deiodination, useful in myxedema coma (rapid clinical effect needed) and in some refractory hypothyroidism (combination T4+T3, controversial). Short half-life produces fluctuating serum levels with intermittent supraphysiologic peaks — one reason T4 monotherapy remains the practical standard<ref name="cytomel-label" />.

PCP:NoindexRenderTest

MDElliottMD — Sat, 13 Jun 2026 06:09:46 GMT

MDElliottMD deleted page PCP:NoindexRenderTest cleanup

Problem:Weight loss

MDElliottMD — Sat, 13 Jun 2026 06:05:32 GMT

Launch A7: honest early-note placeholder (mark-tapped)

← Older revision		Revision as of 06:05, 13 June 2026
Line 1:		Line 1:
	~~''Stub.'' A short~~ clinical description ~~of '''Weight loss''' goes here~~.		<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>

	Intentional weight reduction (overlaps with obesity but covers users without that diagnosis).		Intentional weight reduction (overlaps with obesity but covers users without that diagnosis).

Problem:Vomiting

MDElliottMD — Sat, 13 Jun 2026 06:05:30 GMT

Launch A7: honest early-note placeholder (mark-tapped)

← Older revision		Revision as of 06:05, 13 June 2026
Line 1:		Line 1:
	~~''Stub.'' A short~~ clinical description ~~of '''Vomiting''' goes here~~.		<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>

	Forceful expulsion of gastric contents.		Forceful expulsion of gastric contents.

Problem:Vertigo

MDElliottMD — Sat, 13 Jun 2026 06:05:28 GMT

Launch A7: honest early-note placeholder (mark-tapped)

← Older revision		Revision as of 06:05, 13 June 2026
Line 1:		Line 1:
	~~''Stub.'' A short~~ clinical description ~~of '''Vertigo''' goes here~~.		<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>

	Illusory sensation of self or environmental motion.		Illusory sensation of self or environmental motion.

Problem:VTE prevention or treatment

MDElliottMD — Sat, 13 Jun 2026 06:05:27 GMT

Launch A7: honest early-note placeholder (mark-tapped)

← Older revision		Revision as of 06:05, 13 June 2026
Line 1:		Line 1:
	~~''Stub.'' A short~~ clinical description ~~of '''VTE prevention or treatment''' goes here~~.		<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>

	Prevention or treatment of venous thromboembolism (DVT/PE).		Prevention or treatment of venous thromboembolism (DVT/PE).

Problem:Type 2 diabetes mellitus

MDElliottMD — Sat, 13 Jun 2026 06:05:25 GMT

Launch A7: honest early-note placeholder (mark-tapped)

← Older revision		Revision as of 06:05, 13 June 2026
Line 1:		Line 1:
	~~''Stub.'' A short~~ clinical description ~~of '''Type 2 diabetes mellitus''' goes here~~.		<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>

	Diabetes mellitus, type 2 — insulin resistance with relative insulin deficiency.		Diabetes mellitus, type 2 — insulin resistance with relative insulin deficiency.

Problem:Type 2 Diabetes Mellitus

MDElliottMD — Sat, 13 Jun 2026 06:05:23 GMT

Launch A7: honest early-note + noindex placeholder (mark-tapped)

← Older revision		Revision as of 06:05, 13 June 2026
Line 1:		Line 1:
	~~''Stub.'' A short~~ clinical description ~~of '''Type 2 Diabetes Mellitus''' goes here~~.		<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
			__NOINDEX__

	== Medicines used for Type 2 Diabetes Mellitus ==		== Medicines used for Type 2 Diabetes Mellitus ==

Problem:Type 1 Diabetes Mellitus

MDElliottMD — Sat, 13 Jun 2026 06:05:21 GMT

Launch A7: honest early-note + noindex placeholder (mark-tapped)

← Older revision		Revision as of 06:05, 13 June 2026
Line 1:		Line 1:
	~~''Stub.'' A short~~ clinical description ~~of '''Type 1 Diabetes Mellitus''' goes here~~.		<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
			__NOINDEX__

	== Medicines used for Type 1 Diabetes Mellitus ==		== Medicines used for Type 1 Diabetes Mellitus ==

Problem:Trichotillomania

MDElliottMD — Sat, 13 Jun 2026 06:05:19 GMT

Launch A7: honest early-note + noindex placeholder (mark-tapped)

← Older revision		Revision as of 06:05, 13 June 2026
Line 1:		Line 1:
	~~''Stub.'' A short~~ clinical description ~~of '''Trichotillomania''' goes here~~.		<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
			__NOINDEX__

	== Medicines used for Trichotillomania ==		== Medicines used for Trichotillomania ==

Problem:Treatment-resistant depression (augmentation)

MDElliottMD — Sat, 13 Jun 2026 06:05:17 GMT

Launch A7: honest early-note + noindex placeholder (mark-tapped)

← Older revision		Revision as of 06:05, 13 June 2026
Line 1:		Line 1:
	~~''Stub.'' A short~~ clinical description ~~of '''Treatment~~-~~resistant depression (augmentation)''' goes here~~.		<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
			__NOINDEX__

	== Medicines used for Treatment-resistant depression (augmentation) ==		== Medicines used for Treatment-resistant depression (augmentation) ==

Problem:Treatment-Resistant Depression

MDElliottMD — Sat, 13 Jun 2026 06:05:16 GMT

Launch A7: honest early-note placeholder (mark-tapped)

← Older revision		Revision as of 06:05, 13 June 2026
Line 1:		Line 1:
	~~''Stub.'' A short~~ clinical description ~~of '''Treatment~~-~~Resistant Depression''' goes here~~.		<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>

	A major depressive episode that has not responded adequately to two or more adequate trials of antidepressant medicines.		A major depressive episode that has not responded adequately to two or more adequate trials of antidepressant medicines.

Problem:Traumatic Brain Injury

MDElliottMD — Sat, 13 Jun 2026 06:05:13 GMT

Launch A7: honest early-note + noindex placeholder (mark-tapped)

← Older revision		Revision as of 06:05, 13 June 2026
Line 1:		Line 1:
	~~''Stub.'' A short~~ clinical description ~~of '''Traumatic Brain Injury''' goes here~~.		<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
			__NOINDEX__

	== Medicines used for Traumatic Brain Injury ==		== Medicines used for Traumatic Brain Injury ==

Problem:Tourette Syndrome

MDElliottMD — Sat, 13 Jun 2026 06:05:12 GMT

Launch A7: honest early-note + noindex placeholder (mark-tapped)

← Older revision		Revision as of 06:05, 13 June 2026
Line 1:		Line 1:
	~~''Stub.'' A short~~ clinical description ~~of '''Tourette Syndrome''' goes here~~.		<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
			__NOINDEX__

	== Medicines used for Tourette Syndrome ==		== Medicines used for Tourette Syndrome ==

Problem:Tobacco Use Disorder

MDElliottMD — Sat, 13 Jun 2026 06:05:10 GMT

Launch A7: honest early-note placeholder (mark-tapped)

← Older revision		Revision as of 06:05, 13 June 2026
Line 1:		Line 1:
	~~''Stub.'' A short~~ clinical description ~~of '''Tobacco Use Disorder''' goes here~~.		<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>

	A problematic pattern of tobacco use leading to clinically significant impairment or distress.		A problematic pattern of tobacco use leading to clinically significant impairment or distress.

Problem:Tension-type headache

MDElliottMD — Sat, 13 Jun 2026 06:05:08 GMT

Launch A7: honest early-note placeholder (mark-tapped)

← Older revision		Revision as of 06:05, 13 June 2026
Line 1:		Line 1:
	~~''Stub.'' A short~~ clinical description ~~of '''Tension~~-~~type headache''' goes here~~.		<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>

	Bilateral pressing/tightening headache, mild–moderate intensity.		Bilateral pressing/tightening headache, mild–moderate intensity.

Problem:Stimulant Use Disorder

MDElliottMD — Sat, 13 Jun 2026 06:05:06 GMT

Launch A7: honest early-note + noindex placeholder (mark-tapped)

← Older revision		Revision as of 06:05, 13 June 2026
Line 1:		Line 1:
	~~''Stub.'' A short~~ clinical description ~~of '''Stimulant Use Disorder''' goes here~~.		<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
			__NOINDEX__

	== Medicines used for Stimulant Use Disorder ==		== Medicines used for Stimulant Use Disorder ==

Problem:Specific Learning Disorder with Dyslexia

MDElliottMD — Sat, 13 Jun 2026 06:05:04 GMT

Launch A7: honest early-note + noindex placeholder (mark-tapped)

← Older revision		Revision as of 06:05, 13 June 2026
Line 1:		Line 1:
	~~''Stub.'' A short~~ clinical description ~~of '''Specific Learning Disorder with Dyslexia''' goes here~~.		<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
			__NOINDEX__

	== Medicines used for Specific Learning Disorder with Dyslexia ==		== Medicines used for Specific Learning Disorder with Dyslexia ==

Problem:Specific Learning Disorder with Dyscalculia

MDElliottMD — Sat, 13 Jun 2026 06:05:02 GMT

Launch A7: honest early-note + noindex placeholder (mark-tapped)

← Older revision		Revision as of 06:05, 13 June 2026
Line 1:		Line 1:
	~~''Stub.'' A short~~ clinical description ~~of '''Specific Learning Disorder with Dyscalculia''' goes here~~.		<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
			__NOINDEX__

	== Medicines used for Specific Learning Disorder with Dyscalculia ==		== Medicines used for Specific Learning Disorder with Dyscalculia ==

Problem:Social anxiety disorder

MDElliottMD — Sat, 13 Jun 2026 06:05:01 GMT

Launch A7: honest early-note + noindex placeholder (mark-tapped)

← Older revision		Revision as of 06:05, 13 June 2026
Line 1:		Line 1:
	~~''Stub.'' A short~~ clinical description ~~of '''Social anxiety disorder''' goes here~~.		<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
			__NOINDEX__

	== Medicines used for Social anxiety disorder ==		== Medicines used for Social anxiety disorder ==

Problem:Social Anxiety Disorder

MDElliottMD — Sat, 13 Jun 2026 06:04:59 GMT

Launch A7: honest early-note + noindex placeholder (mark-tapped)

← Older revision		Revision as of 06:04, 13 June 2026
Line 1:		Line 1:
	~~''Stub.'' A short~~ clinical description ~~of '''Social Anxiety Disorder''' goes here~~.		<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
			__NOINDEX__

	== Medicines used for Social Anxiety Disorder ==		== Medicines used for Social Anxiety Disorder ==

Problem:Smoking cessation

MDElliottMD — Sat, 13 Jun 2026 06:04:57 GMT

Launch A7: honest early-note placeholder (mark-tapped)

← Older revision		Revision as of 06:04, 13 June 2026
Line 1:		Line 1:
	~~''Stub.'' A short~~ clinical description ~~of '''Smoking cessation''' goes here~~.		<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>

	Tobacco/nicotine cessation pharmacotherapy.		Tobacco/nicotine cessation pharmacotherapy.

Problem:Sensory Processing Sensitivity

MDElliottMD — Sat, 13 Jun 2026 06:04:55 GMT

Launch A7: honest early-note + noindex placeholder (mark-tapped)

← Older revision		Revision as of 06:04, 13 June 2026
Line 1:		Line 1:
	~~''Stub.'' A short~~ clinical description ~~of '''Sensory Processing Sensitivity''' goes here~~.		<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
			__NOINDEX__

	== Medicines used for Sensory Processing Sensitivity ==		== Medicines used for Sensory Processing Sensitivity ==

Problem:Sensory Processing Disorder

MDElliottMD — Sat, 13 Jun 2026 06:04:53 GMT

Launch A7: honest early-note + noindex placeholder (mark-tapped)

← Older revision		Revision as of 06:04, 13 June 2026
Line 1:		Line 1:
	~~''Stub.'' A short~~ clinical description ~~of '''Sensory Processing Disorder''' goes here~~.		<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
			__NOINDEX__

	== Medicines used for Sensory Processing Disorder ==		== Medicines used for Sensory Processing Disorder ==

Problem:Seasonal Affective Disorder

MDElliottMD — Sat, 13 Jun 2026 06:04:52 GMT

Launch A7: honest early-note + noindex placeholder (mark-tapped)

← Older revision		Revision as of 06:04, 13 June 2026
Line 1:		Line 1:
	~~''Stub.'' A short~~ clinical description ~~of '''Seasonal Affective Disorder''' goes here~~.		<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
			__NOINDEX__

	== Medicines used for Seasonal Affective Disorder ==		== Medicines used for Seasonal Affective Disorder ==

Problem:Schizotypal Personality Disorder

MDElliottMD — Sat, 13 Jun 2026 06:04:50 GMT

Launch A7: honest early-note + noindex placeholder (mark-tapped)

← Older revision		Revision as of 06:04, 13 June 2026
Line 1:		Line 1:
	~~''Stub.'' A short~~ clinical description ~~of '''Schizotypal Personality Disorder''' goes here~~.		<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
			__NOINDEX__

	== Medicines used for Schizotypal Personality Disorder ==		== Medicines used for Schizotypal Personality Disorder ==

Problem:Schizophrenia

MDElliottMD — Sat, 13 Jun 2026 06:04:49 GMT

Launch A7: honest early-note + noindex placeholder (mark-tapped)

← Older revision		Revision as of 06:04, 13 June 2026
Line 1:		Line 1:
	~~''Stub.'' A short~~ clinical description ~~of '''Schizophrenia''' goes here~~.		<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
			__NOINDEX__

	== Medicines used for Schizophrenia ==		== Medicines used for Schizophrenia ==

Problem:Schizoid Personality Disorder

MDElliottMD — Sat, 13 Jun 2026 06:04:47 GMT

Launch A7: honest early-note + noindex placeholder (mark-tapped)

← Older revision		Revision as of 06:04, 13 June 2026
Line 1:		Line 1:
	~~''Stub.'' A short~~ clinical description ~~of '''Schizoid Personality Disorder''' goes here~~.		<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
			__NOINDEX__

	== Medicines used for Schizoid Personality Disorder ==		== Medicines used for Schizoid Personality Disorder ==

Problem:Schizoaffective Disorder

MDElliottMD — Sat, 13 Jun 2026 06:04:46 GMT

Launch A7: honest early-note + noindex placeholder (mark-tapped)

← Older revision		Revision as of 06:04, 13 June 2026
Line 1:		Line 1:
	~~''Stub.'' A short~~ clinical description ~~of '''Schizoaffective Disorder''' goes here~~.		<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
			__NOINDEX__

	== Medicines used for Schizoaffective Disorder ==		== Medicines used for Schizoaffective Disorder ==

Problem:Rosacea

MDElliottMD — Sat, 13 Jun 2026 06:04:44 GMT

Launch A7: honest early-note placeholder (mark-tapped)

← Older revision		Revision as of 06:04, 13 June 2026
Line 1:		Line 1:
	~~''Stub.'' A short~~ clinical description ~~of '''Rosacea''' goes here~~.		<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>

	Chronic facial erythema and telangiectasias, sometimes papulopustular.		Chronic facial erythema and telangiectasias, sometimes papulopustular.

Problem:Rheumatoid Arthritis

MDElliottMD — Sat, 13 Jun 2026 06:04:42 GMT

Launch A7: honest early-note + noindex placeholder (mark-tapped)

← Older revision		Revision as of 06:04, 13 June 2026
Line 1:		Line 1:
	~~''Stub.'' A short~~ clinical description ~~of '''Rheumatoid Arthritis''' goes here~~.		<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
			__NOINDEX__

	== Medicines used for Rheumatoid Arthritis ==		== Medicines used for Rheumatoid Arthritis ==

Problem:Restless Legs Syndrome

MDElliottMD — Sat, 13 Jun 2026 06:04:40 GMT

Launch A7: honest early-note + noindex placeholder (mark-tapped)

← Older revision		Revision as of 06:04, 13 June 2026
Line 1:		Line 1:
	~~''Stub.'' A short~~ clinical description ~~of '''Restless Legs Syndrome''' goes here~~.		<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
			__NOINDEX__

	== Medicines used for Restless Legs Syndrome ==		== Medicines used for Restless Legs Syndrome ==

Problem:Rejection Sensitivity Dysphoria

MDElliottMD — Sat, 13 Jun 2026 06:04:38 GMT

Launch A7: honest early-note + noindex placeholder (mark-tapped)

← Older revision		Revision as of 06:04, 13 June 2026
Line 1:		Line 1:
	~~''Stub.'' A short~~ clinical description ~~of '''Rejection Sensitivity Dysphoria''' goes here~~.		<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
			__NOINDEX__

	== Medicines used for Rejection Sensitivity Dysphoria ==		== Medicines used for Rejection Sensitivity Dysphoria ==

Problem:Recreational use

MDElliottMD — Sat, 13 Jun 2026 06:04:37 GMT

Launch A7: honest early-note placeholder (mark-tapped)

← Older revision		Revision as of 06:04, 13 June 2026
Line 1:		Line 1:
	~~''Stub.'' A short~~ clinical description ~~of '''Recreational use''' goes here~~.		<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>

	Use of a medicine outside an approved medical indication for its subjective effects. Documented here as a real use category, without endorsement.		Use of a medicine outside an approved medical indication for its subjective effects. Documented here as a real use category, without endorsement.

Problem:Public speaking anxiety

MDElliottMD — Sat, 13 Jun 2026 06:04:35 GMT

Launch A7: honest early-note placeholder (mark-tapped)

← Older revision		Revision as of 06:04, 13 June 2026
Line 1:		Line 1:
	~~''Stub.'' A short~~ clinical description ~~of '''Public speaking anxiety''' goes here~~.		<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>

	Situational anxiety around public speaking or performance.		Situational anxiety around public speaking or performance.

Problem:Psoriatic Arthritis

MDElliottMD — Sat, 13 Jun 2026 06:04:33 GMT

Launch A7: honest early-note + noindex placeholder (mark-tapped)

← Older revision		Revision as of 06:04, 13 June 2026
Line 1:		Line 1:
	~~''Stub.'' A short~~ clinical description ~~of '''Psoriatic Arthritis''' goes here~~.		<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
			__NOINDEX__

	== Medicines used for Psoriatic Arthritis ==		== Medicines used for Psoriatic Arthritis ==

Problem:Psoriasis

MDElliottMD — Sat, 13 Jun 2026 06:04:32 GMT

Launch A7: honest early-note placeholder (mark-tapped)

← Older revision		Revision as of 06:04, 13 June 2026
Line 1:		Line 1:
	~~''Stub.'' A short~~ clinical description ~~of '''Psoriasis''' goes here~~.		<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>

	Chronic immune-mediated scaling skin disease.		Chronic immune-mediated scaling skin disease.

Problem:Pruritus

MDElliottMD — Sat, 13 Jun 2026 06:04:30 GMT

Launch A7: honest early-note placeholder (mark-tapped)

← Older revision		Revision as of 06:04, 13 June 2026
Line 1:		Line 1:
	~~''Stub.'' A short~~ clinical description ~~of '''Pruritus''' goes here~~.		<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>

	Itching, generalized or localized.		Itching, generalized or localized.

Problem:Premenstrual Dysphoric Disorder

MDElliottMD — Sat, 13 Jun 2026 06:04:28 GMT

Launch A7: honest early-note + noindex placeholder (mark-tapped)

← Older revision		Revision as of 06:04, 13 June 2026
Line 1:		Line 1:
	~~''Stub.'' A short~~ clinical description ~~of '''Premenstrual Dysphoric Disorder''' goes here~~.		<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
			__NOINDEX__

	== Medicines used for Premenstrual Dysphoric Disorder ==		== Medicines used for Premenstrual Dysphoric Disorder ==

Problem:Premature ejaculation

MDElliottMD — Sat, 13 Jun 2026 06:04:26 GMT

Launch A7: honest early-note + noindex placeholder (mark-tapped)

← Older revision		Revision as of 06:04, 13 June 2026
Line 1:		Line 1:
	~~''Stub.'' A short~~ clinical description ~~of '''Premature ejaculation''' goes here~~.		<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
			__NOINDEX__

	== Medicines used for Premature ejaculation ==		== Medicines used for Premature ejaculation ==

Problem:Postural Orthostatic Tachycardia Syndrome

MDElliottMD — Sat, 13 Jun 2026 06:04:25 GMT

Launch A7: honest early-note + noindex placeholder (mark-tapped)

← Older revision		Revision as of 06:04, 13 June 2026
Line 1:		Line 1:
	~~''Stub.'' A short~~ clinical description ~~of '''Postural Orthostatic Tachycardia Syndrome''' goes here~~.		<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
			__NOINDEX__

	== Medicines used for Postural Orthostatic Tachycardia Syndrome ==		== Medicines used for Postural Orthostatic Tachycardia Syndrome ==

Problem:Posttraumatic Stress Disorder

MDElliottMD — Sat, 13 Jun 2026 06:04:23 GMT

Launch A7: honest early-note + noindex placeholder (mark-tapped)

← Older revision		Revision as of 06:04, 13 June 2026
Line 1:		Line 1:
	~~''Stub.'' A short~~ clinical description ~~of '''Posttraumatic Stress Disorder''' goes here~~.		<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
			__NOINDEX__

	== Medicines used for Posttraumatic Stress Disorder ==		== Medicines used for Posttraumatic Stress Disorder ==

Problem:Polycystic Ovary Syndrome

MDElliottMD — Sat, 13 Jun 2026 06:04:21 GMT

Launch A7: honest early-note + noindex placeholder (mark-tapped)

← Older revision		Revision as of 06:04, 13 June 2026
Line 1:		Line 1:
	~~''Stub.'' A short~~ clinical description ~~of '''Polycystic Ovary Syndrome''' goes here~~.		<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
			__NOINDEX__

	== Medicines used for Polycystic Ovary Syndrome ==		== Medicines used for Polycystic Ovary Syndrome ==

Problem:Persistent Depressive Disorder (Dysthymia)

MDElliottMD — Sat, 13 Jun 2026 06:04:19 GMT

Launch A7: honest early-note + noindex placeholder (mark-tapped)

← Older revision		Revision as of 06:04, 13 June 2026
Line 1:		Line 1:
	~~''Stub.'' A short~~ clinical description ~~of '''Persistent Depressive Disorder (Dysthymia)''' goes here~~.		<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
			__NOINDEX__

	== Medicines used for Persistent Depressive Disorder (Dysthymia) ==		== Medicines used for Persistent Depressive Disorder (Dysthymia) ==